Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 61.33 CNY -5.5% Market Closed
Market Cap: 45.5B CNY
Have any thoughts about
Hangzhou Tigermed Consulting Co Ltd?
Write Note

Hangzhou Tigermed Consulting Co Ltd
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hangzhou Tigermed Consulting Co Ltd
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Cash Paid for Dividends
-ÂĄ643.3m
CAGR 3-Years
-27%
CAGR 5-Years
-25%
CAGR 10-Years
-31%
WuXi AppTec Co Ltd
SSE:603259
Cash Paid for Dividends
-ÂĄ2.7B
CAGR 3-Years
-42%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Cash Paid for Dividends
-ÂĄ820.8m
CAGR 3-Years
-30%
CAGR 5-Years
-63%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
MGI Tech Co Ltd
SSE:688114
Cash Paid for Dividends
-ÂĄ155.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hangzhou Tigermed Consulting Co Ltd
Glance View

Market Cap
45.5B CNY
Industry
Life Sciences Tools & Services

Hangzhou Tigermed Consulting Co., Ltd. is a leading clinical trial and consulting organization based in China, dedicated to facilitating the development of innovative medical therapies. Founded in 2002, the company has rapidly ascended to prominence by leveraging its deep expertise in clinical research while providing comprehensive services that encompass all phases of clinical trials. With a robust portfolio that includes over 4,000 completed projects, Tigermed stands out for its strong focus on quality, efficiency, and regulatory compliance. Serving a diverse clientele of pharmaceutical and biotechnology companies, the firm positions itself as a vital partner in navigating the complexities of the drug development process, particularly in fast-growing Asian markets. An investor looking at Tigermed will find a company that is not only well-established but also poised for significant growth amidst rising global healthcare demands. With a strategic emphasis on expanding its geographic footprint and enhancing technological capabilities, Tigermed is capitalizing on the increasing investment in life sciences, particularly in China and surrounding regions. By harnessing big data analytics and innovative methodologies, the company is well-equipped to streamline clinical operations, reduce costs, and accelerate time-to-market for life-saving treatments. As the global healthcare landscape continues to evolve, Tigermed’s commitment to fostering advancements in clinical research places it in an advantageous position, making it an attractive prospect for investors seeking exposure in the burgeoning healthcare sector.

Intrinsic Value
70.64 CNY
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Hangzhou Tigermed Consulting Co Ltd's Cash Paid for Dividends?
Cash Paid for Dividends
-643.3m CNY

Based on the financial report for Sep 30, 2024, Hangzhou Tigermed Consulting Co Ltd's Cash Paid for Dividends amounts to -643.3m CNY.

What is Hangzhou Tigermed Consulting Co Ltd's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 10Y
-31%

Over the last year, the Cash Paid for Dividends growth was -9%. The average annual Cash Paid for Dividends growth rates for Hangzhou Tigermed Consulting Co Ltd have been -27% over the past three years , -25% over the past five years , and -31% over the past ten years .

Back to Top